Can Nonprofit Odylia Blaze a New Path Forward for Stalling Gene Therapies? – Xconomy
Xconomy |
Can Nonprofit Odylia Blaze a New Path Forward for Stalling Gene Therapies?
Xconomy After decades of ups and downs, gene therapy, which offers a long-lasting genetic fix for a disease, has arrived. A product from Spark Therapeutics called Luxturna, for a rare, inherited type of vision loss, recently became the first-ever approved gene … |
